Welcome to Inform Genomics, Inc.
Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products.
Our products are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Our lead development program is in oncology supportive care, with 2 major products currently in development: OnPART™ and HSCT/Mucositis™.
The company’s novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. Our analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. These predictive networks have shown biologic validity.
Along with our advanced analytics, we also are dedicated to helping physicians translate this complex information in ways that are meaningful to patients. Our goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient’s needs and values.
Product Development Program
Our lead product development program is focused on cancer supportive care—an area of high unmet clinical need. The products in this program—OnPART™ and HSCT/Mucositis™—are designed not only to predict a patient’s risk for developing common chemotherapy-related side effects, but also to assess a patient’s willingness to tolerate those side effects. Knowing these individual risks and patient priorities in advance of therapy can foster shared clinical decision-making, enhance informed consent, and help shape a more precise and effective cancer care plan.
Our products are designed to reduce the high patient, clinical, and economic burden associated with managing chemotherapy-related side effects. These new product candidates have the potential to create a new standard of care in today’s oncology practice for the benefit of patients, providers, and payors alike.
The US market opportunity for our lead products in cancer supportive care exceeds $1 billion annually.